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Background. Aristolochia species are nephrotoxic and car-
cinogenic. Recent studies showed that aristolochic acid (AA)
could induce acute renal failure and tubular lesions in several
species and available evidences demonstrate the unequivocal
role of AA in so called Chinese herbs nephropathy.
Methods. A series of AA derivatives isolated from Aris-
tolochia spp. were analyzed for their nephrotoxic potential us-
ing the neutral red dye exclusion assay in cultures of LLC-PK1
cells. The structural relationships between AA I and its ana-
logues were compared with their cytotoxic effects to predict
structural determinants for AA toxicity. Further, caspase-3 as-
say was performed on toxic compounds to determine if caspases,
the enzymes that play a critical role in apoptosis are involved
in AA-induced cytotoxicity.
Results. AA I was found to be most toxic followed by AA
II, AA VIIIa, and AA Ia in decreasing levels of toxicity. The
other compounds, nitrophenanthrene carboxylic acid analogues
of AA I, aristolactams, and other derivatives did not exhibit con-
siderable toxicity. The results showed significant relationships
between cytotoxicity of AA compounds and the localization of
functional groups in their structure. Analogues containing hy-
droxyl groups diminished cytotoxicity. The demethylated ana-
logues of AA I are markedly less active. The negative impact on
cytotoxicity was found on nitroreduction of AA I. AA induced
caspase activation was also observed.
Conclusion. These cytotoxic data suggest that the nitro and
methoxy groups are critical determinants of nephrotoxicologic
potency of AA.
Aristolochic acid (AA) and their derivatives are struc-
turally related nitrophenanthrene carboxylic acids iso-
lated from Aristolochia spp. (e.g., Aristolochia fangchi,
Aristolochia clematis, Aristolochia manshuriensis, Aris-
tolochia contorta). Herbal drugs derived from Aris-
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tolochia plants have been used as medicine in obstetrics
and in the treatment of snake bites [1]. The plant ex-
tracts have also been used for the therapy of arthritis,
gout, rheumatism, and festering wounds [2, 3]. The anti-
inflammatory properties of AA have encouraged its use
in various drug formulations in Germany [4, 5] until it was
identified as a potential carcinogen in rodents by Mengs
[6, 7] in late 1980s. Acute AA intoxication resulted in
acute renal failure, whereas chronic administration in-
duced multisystemic tumors in rats.
In the early 1990s, ingestion of AA was incriminated in
the outbreak of the so-called “Chinese herbs nephropa-
thy” (CHN), a severe tubulointerstitial nephritis initially
described in Belgium women who had followed a partic-
ular slimming regimen that included the Chinese herbs,
Stephania tetrandra and Magnolia officinalis [8, 9]. Be-
cause of name similarities, one of the herbs S. tetrandra
(known in traditional Chinese medicine by the Pin Yin
name Han fang ji) was inadvertently replaced in weight-
reducing pills by A. fangchi (Pin Yin name Guang fang
ji), which contains nephrotoxic AA [10]. In addition to a
rapidly progressive interstitial renal failure due to partic-
ularly severe fibrosis, the clinical course of CHN is com-
plicated by tumoral transformations in the urothelium
[11]. The observation of typical renal interstitial fibrosis
and urothelial malignancy in patients from other Euro-
pean [12, 13] and Asian countries [14, 15] and also in
the United States [16] who were exposed to Aristolochia
spp. containing AA conclusively demonstrated the etio-
logic role of AA in the genesis of the disease [17]. There-
fore, it has been proposed to designate the interstitial
nephropathy in which the unequivocal role of AA has
been fully documented as aristolochic acid nephropathy
(AAN) [18].
Several studies have established AA as a strong
nephrotoxin and genotoxic mutagen [19–23]. Subse-
quently, all pharmaceutical preparations containing AA
have been withdrawn from the market in many coun-
tries. Recently, the federal Food and Drug Administra-
tion (FDA) has issued an alert advising the consumers to
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immediately discontinue the use of any botanical prod-
ucts containing AA [24].
Inasmuch as AA nephrotoxicity and carcinogenicity
represents a serious health risk, there exists increasing
demand to understand the structural requirements of var-
ious AA compounds derived from Aristolochia spp., for
their nephrotoxicity. The rationale behind the present
toxicological study is to compare the cytotoxic potential
of AA I with a series of its analogues in order to investi-
gate the structural determinants of AA I toxicity.
The involvement of AA in the early dysfunction of
proximal tubular cells during CHN and their causal rela-
tionship between DNA adduct formation have been re-
ported [25] and also reviewed [11]. Several studies have
employed cultures of LLC-PK1 cell lines, which are prox-
imal tubular cells from pig kidney as in vitro system for
investigating nephrotoxicity of various compounds [26–
28]. We report here the results of studies designed to eval-
uate the cytotoxicity of various compounds isolated from
A. fangchi and A. contorta with respect to their chemical
structure on LLC-PK1 cells. This in vitro model system
could be somewhat reflective of the clinical situation with
regard to AA-induced nephrotoxicity.
AA might have direct cytotoxic effect, inducing renal
tubular lesions and subsequent acellular interstitial fibro-
sis. Alternatively, AA DNA adducts could induce muta-
tions responsible not only for the development of AAN-
associated malignancies [17] but also for the fibrotic
process [22, 29]. Concerning the possible mechanism
of AA-mediated acute tubular injury, pervious reports
showed that cell apoptosis played an important role in
the development of the insult [30–32]. The increase in in-
tracellular calcium ion concentration has been suggested
as one of the reasons for AA I–induced apoptosis in LLC-
PK1 cells [30]. Cells generally require specialized machin-
ery to undergo apoptosis. The central component of this
machinery is a proteolytic system involving a family of
proteases called caspases. These enzymes participate in
a cascade that is triggered in response to proapoptotic
signals and culminates in cleavage of a set of proteins,
resulting in the disassembly of the cell [33]. When apop-
tosis is induced, procaspases are proteolytically cleaved
and reassemble to form active caspases. In the present
study, the role of caspases in AA-induced apoptosis in
proximal tubular cells has also been investigated to un-
derstand the mechanism of AA toxicity.
METHODS
Cell line maintenance
Cells used in this assay were LLC-PK1 cells, renal
epithelial cells from pig, and BT-549 cells purchased
from American Type Culture Collection (Bethesda, MD,
USA). Cells were maintained in RPMI 1640 medium
(Gibco Invitrogen Corporation, Carlsbad, CA, USA)
Table 1. Physical chemical properties of test compounds
Name Color Solubility
AA-I Yellow Methanol, DMSO
AA-II Yellow Methanol, DMSO
AA VIIIa Yellow Methanol, DMSO
AA Ia Yellow Methanol, DMSO
Aristolic acid Yellow white CHCl3, DMSO
AA-III Yellow Methanol, DMSO
7-OH AA-I Yellow Methanol, DMSO
AA VIa Yellow Methanol, DMSO
AA-C Yellow red Methanol, DMSO
AA-D Yellow red Methanol, DMSO
Aristofolin B Yellow white CHCl3, DMSO
Aristolactam I Yellow Methanol, DMSO
Aristolactam II Yellow Methanol, DMSO
Aristolactam I-N-glu Yellow Methanol, DMSO
Aristolactam C-N-glu Yellow Methanol, DMSO
Aristolactam BIV Yellow Methanol, DMSO
Aristolactam A IIIa Yellow Methanol, DMSO
Ariskanin B Yellow Methanol, DMSO
p- OH benzoic acid White Methanol, DMSO
3-OH 4-methoxy benzoic acid White Methanol, DMSO
4-OH 2,6, dimethoxy benzoic acid White Methanol, DMSO
Emodin Yellow red Methanol, DMSO
Abbreviations are: AA, aristolochic acid; DMSO, dimethyl sulfoxide.
containing fetal bovine serum (FBS) (Atlanta Biologi-
cals, Inc., Atlanta, GA, USA) (5% for LLC-PK1 and 10%
for BT-549) and penicillin/streptomycin in a humidified
atmosphere of 5% CO2 at 37◦C.
AA compounds investigated in this study
The AA compounds used in this nephrotoxic study
were isolated in our laboratory from Aristolochia plants,
A. contorta and A. fangchi by standard isolation proto-
cols and their chemical structure have been identified and
confirmed by spectroscopic methods (data not shown).
Based on their structure, these compounds were catego-
rized into nitrophenanthrene carboxylic acid derivatives,
aristolactams, and benzoic acid derivatives. The chemical
structures of these compounds are available elsewhere
[34, 35]. The physical chemical properties of the test com-
pounds are given in Table 1.
Eleven nitrophenantherene caroboxylic acid deriva-
tives of AA, namely AA I, AA II, AA III, AA Ia, 7-
OH AA I, AA IVa, AA VIIIa, AA C, AA D, aris-
tolic acid, and aristofolin B (Table 1), and seven com-
pounds of aristolactams derivatives, namely aristolac-
tam I, aristolactam II, aristolactam N-beta-D-glucoside,
aristolactam-C-N-glu, aristolactam B IV, aristolactam A
IIIa, and ariskanin B, and benzoic acid derivatives, p-OH
benzoic acid, 3-OH-4-methoxy benzoic acid, 4-OH-2,6-
dimethoxy-benzoic acid, and emodin, were selected for
the evaluation of cytotoxicity.
Sample preparation
The test compounds were originally suspended in
dimethyl sulfoxide (DMSO) at a concentration of
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20 mg/mL and they were further diluted to required con-
centration with cell culture media. The graded concentra-
tions from 1 lmol/L to 300 lmol/L were used to determine
the toxicity. An IC50 value of 300 lmol/L or above was
considered as nontoxic.
Neutral red assay
An important aspect of this assay has been its utiliza-
tion in establishing structure activity relationships for the
series of related compounds [36, 37]. This assay proce-
dure was adapted from Babich and Borenfreund [38].
The principle of this assay, which is based on lysoso-
mal membrane integrity, has been previously described
[39]. Briefly, the cells were seeded at the density of 2.5 ×
104 cells in a volume of 0.25 mL media per well in 96-
well microplate. The cell number per well was selected
based on the density found to display linear growth during
24 hours of incubation in pilot studies (data not shown).
Twenty-four hours after seeding, the cells were replaced
with 0.25 mL of fresh media and graded concentrations
of test compounds were added. DMSO was used as the
control. Doxorubicin was used as the positive control and
hederasaponin C was used as the negative control. After
the cells are exposed to test compounds for 48 hours, the
medium was replaced with 0.1 mL of fresh serum-free
media containing neutral red (16 6lg/mL) (Sigma Chem-
ical Co., St. Louis, MO, USA) and incubation with dye
continued for another 90 minutes to allow for uptake of
vital dye into lysosomes of viable, uninjured cells. Cells
were then washed with saline and incorporated dye from
viable cells was liberated by lysis with 0.33% HCl in iso-
propanol and the absorbance was read at 540 nm which
directly correlates with cell viability. Quantitation of the
extracted dye was shown to be linear with cell numbers,
both by direct cell counts and by protein determination
of cell populations [36, 37, 39].
Data analysis
The mean absorbance of toxicant treated wells was di-
vided by mean absorbance of control wells and multiplied
by 100 to yield the percent viability. The intra- and interas-
say variations for each compound were determined (N =
3 and N = 2, respectively). The dose response curve of
relative cell viability was plotted to delineate the concen-
trations of AA compounds that inhibited cell growth to
50% (IC50 value).
Caspase 3/7 activity assay
Caspase 3/7 activity was estimated using Caspase
GloTM 3/7 luminescent assay kit (Promega Corpora-
tion, Madison, WI, USA) according to manufacturer’s
instructions. A total of 0.01 × 106 cells were seeded in
white walled 96-well luminometer plate and incubated
for 24 hours at 37◦C. The cells were replaced with fresh
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Fig. 1. Comparison of dose-response curve of toxic aristolochic acid
(AA) derivatives with controls. LLC-PK1 cells were treated with test
compounds at given concentrations for 48 hours and cytotoxic potential
was compared with dimethyl sulfoxide (DMSO)-treated controls using
neutral red assay as described in the Methods section. Doxorubicin
was used as positive control and hederasaponin C was used as negative
control. IC 50 values were as follows: doxorubicin 1.7 lmol/L, AA I 10
lmol/L, AA II 80 lmol/L, AA VIIIa 70 lmol/L, and AA Ia 200 lmol/L.
Values are mean ± SD (N = 6).
media containing the test compounds and the incuba-
tion was continued for another 48 hours. Doxorubicin
was used as the positive control and DMSO-treated cells
were used as negative control for the assay. Blank con-
tained DMSO and cell culture medium without cells. The
assay provides a proluminescent caspase 3/7 substrate,
which contains the tetrapeptide sequence Asp-Glu-Val-
Asp (DEVD), in a reagent optimized for caspase activ-
ity, luciferase activity, and cell lysis. The addition of equal
volume of this single reagent in “add-mix-measure” for-
mat results in cell lysis, followed by caspase cleavage of
the substrate and generation of a “glow-type” lumines-
cent signal, produced by luciferase. The luminescence was
measured at 30 minutes after the addition of the reagent
using a Packard microplate scintillation counter in single
photon mode and the luminescense is proportional to the
amount of caspase activity present. DEVD-fmk was used
as caspase 3/7 inhibitor. The data are expressed as mean
± SD. Comparisons were performed by unpaired Student
t test analysis.
Control experiments from both neutral red assay and
caspase 3/7 activity assay demonstrated that DMSO had
no toxic effect on this cell line.
RESULTS
Effect of nitrophenantherene caroboxylic
acid derivatives on LLC-PK1 cell line
Cytotoxic effects of eleven compounds of nitrophenan-
therene caroboxylic acid derivatives on LLC-PK1 cell vi-
ability are shown in Figures 1 and 3. Out of these AA I,
AA II, AA VIIIa, and AA Ia exhibited dose-dependent
effects and the ranking by IC50 was AA I >AA VIIIa
> AA II >AA Ia (Fig. 1). AA I was found to be an
intense cytotoxic compound that elicits maximum toxi-
city (IC50 value 10 lmol/L) among all the compounds
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Fig. 2. Comparison of dose-response curve of aristolochic acid (AA)
compounds in non-renal cell line. BT-549 cells were treated with test
compounds at given concentrations for 48 hours and cytotoxic poten-
tial was compared with dimethyl sulfoxide (DMSO)-treated controls
using neutral red assay as described in the Methods section. IC50 of
doxorubicin 2 lmol/L. Values are mean ± SD (N = 6).
examined on this cell line. AA VIIIa have an IC50 value of
70 lmol/L followed by AA II (IC50 value 80 lmol/L) and
AA Ia (IC50 value 200 lmol/L). Doxorubicin, a known
cytotoxic agent (as a positive control) showed very high
toxicity with IC50 value of 1.7 lmol/L. Hederasaponin C
isolated from Clematis spp. was not toxic to this cell line
(negative control).
The above compounds that showed toxicity to renal
cell line were tested on human epithelial breast cell line
BT-549, to evaluate their kidney specific cytotoxic action.
All these compounds have failed to show toxic effect on
this breast cell line (Fig. 2), indicating their specificity
towards nephrotoxic action. From Figure 3, it is evident
that the rest of the nitrophenantherene derivatives from
Aristolochia spp. were not toxic to LLC-PK1 cell line.
Effect of aristolactam derivatives on LLC-PK1 cell line
Seven aristolactam derivatives were evaluated for their
toxic properties on the LLC-PK1 cell line in graded con-
centrations and none of them were found to be toxic in
this cell line (Fig. 4).
Effect of other minor AA derivatives
on LLC-PK1 cell line
Several other compounds present in Aritolochia plants
in minor quantities like benzoic acid derivatives, p-OH
benzoic acid, 3-OH-4-methoxy benzoic acid, 4-OH-2,6-
dimethoxy-benzoic acid, and emodin were also nontoxic
(Fig. 5).
Cell apoptosis and caspase activation
To investigate whether caspases play a role in AA-
induced proximal tubular cell injury and apoptosis,
caspase-3/7 assay was performed using AA compounds.
The activity of caspase-3/7 was estimated using labeled
substrate, DEVD-luciferin. The caspase activity was dra-
matically induced by AA I, AA II, AA Ia, and AA VIIIa
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Fig. 3. Comparison of dose-response curve of non-toxic aristolochic
acid (AA) derivatives. LLC-PK1 cells were treated with AA compounds
at given concentrations for 48 hours and cytotoxic potential was com-
pared with dimethyl sulfoxide (DMSO)-treated controls using neutral
red assay as described in the Methods section. Values are mean ± SD
(N = 6).
and also by the mixture of AA I and II (Fig. 6) in a dose
dependent manner (data not shown). The doses of these
compounds that showed 100% inhibition of cell growth
in neutral red assay induced maximum stimulation of cas-
pase activity on this cell line. AA mixture induced activa-
tion of caspase was reduced in the presence of inhibitor,
suggesting the specificity of caspase induction by these
compounds. None of the other AA compounds (at the
concentration of 300 lmol/L) were able to induce cas-
pase activities significantly.
DISCUSSION
Renal proximal tubular cells isolated from humans
and animals can serve as useful tools for assessing the
biochemical and physiologic functions of the kidney
[26]. These cells participate in the excretion of biogenic
metabolites, xenobiotics, and drugs and represent a pri-
mary target site for several toxic compounds including
AA in vivo [6], in vitro [25], and also in humans [40, 41].
In CHN, the proximal tubular cells are characterized by
interstitial fibrosis [22] and the presence of extensively
flattened cells has also been reported in acute toxic con-
ditions [40, 41]. The cellular mechanisms of AA toxicity
have also been delineated in the opossum kidney cell line,
another model of proximal tubular cells [25].
LLC-PK1 is an established cell line derived from nor-
mal porcine kidneys that has been widely used to study
renal functions [42]. Studies indicate that LLC-PK1 cells
retain many properties of native proximal tubular ep-
ithelial cells [43]. In culture, these cells form an oriented
monolayer with microvilli at their apical side and exhibit
typical activities of renal proximal tubular cells such as
transport of hexose, amino acids, phosphate, and organic
cations [44]. In the present study, the LLC-PK1 cell line
has been used as an in vitro model system to evaluate the
toxicity of AA derivatives.
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Fig. 4. Comparison of dose-response curve
of aristolactam derivatives. LLC-PK1 cells
were treated with aristolochic acid (AA) com-
pounds at given concentrations for 48 hours
and cytotoxic potential was compared with
dimethyl sulfoxide (DMSO)-treated controls
using neutral red assay as described in the
Methods section. Values are mean ± SD
(N = 6).
Nitroarenes are common environmental contaminants
that may represent a risk to human health. Conse-
quently, observations regarding the toxic potential of
nitrophenanthrene derivatives are of substantial inter-
est. AA, the active principle extracted from Aristolochia
spp., contain predominantly AA I and AA II, which
are nitrophenanthrene carboxylic acid derivatives. Aris-
tolochic spp. also contain several other derivatives such
as 7-hydroxy AA I, AA Ia, AA-C, AA D, AA III, AA
VIa, AA VIIIa, aristolic acid, aristofolin B, aristolac-
tams, and few benzoic acid derivatives in various quanti-
ties [11, 45]. From the results of the present study, we
observe some correlation between the chemical struc-
ture and the toxicity profile of AA and their derivatives.
Structure-toxicity analysis shows that the ring structures,
the side chains and even their localization are critical de-
terminants for toxic properties. Table 2 depicts the struc-
ture of nitrophenanthrene carboxylic acid compounds.
In this structure, the “nitro” (−NO2) group in R4 posi-
tion and “methoxy” (−OCH3) group in R1 position are
critical determinants for maximum toxicity as observed
for AA I, which is 8-methoxy-6-nitro-phenanthro-(3,4-
d)-1,3-dioxolo-5-carboxylic acid. Any modification from
AA I structure, namely the addition, deletion, substitu-
tion, or replacements of the position of these side chains,
drastically reduce toxicity. Since AA I is the most toxic
compound identified thus far, its toxicity was compared
with that of its structural analogues isolated from Aris-
tolochia spp. Further discussion about toxicity is based on
AA I structure.
In AA II, the removal of “methoxy” group from R1 po-
sition reduces the toxicity. AA II, which differs from AA I
by one “methoxy” group, has an IC50 value of 80 lmol/L
and is far less toxic than AA I (IC50 10 lmol/L). AA
VIIIa has an IC50 value of 70 lmol/L. Reduced toxicity
could be due to the combined effect of the rearrange-
ment of the methoxy group position (from R1 to R2) and
the addition of the hydroxyl group at R1 position. In AA
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Fig. 5. Comparison of dose-response curve of benzoic acid derivatives
and emodin. LLC-PK1 cells were treated with aristolochic acid (AA)
compounds at given concentrations for 48 hours and cytotoxic potential
was compared with dimethyl sulfoxide (DMSO)-treated controls using
neutral red assay as described in the Methods section. Values are mean±
SD (N = 6).
Ia, O-demethylation (i.e., by substitution of “hydroxyl”
group in the place of “methoxy” group at R1 position),
reduces the toxicity to 200 lmol/L. In aristolic acid re-
ductive replacement of nitro group from R4 position ren-
ders the compound nontoxic. In aristofolin B reductive
replacement of nitro group from R4 position and addi-
tion of hydroxyl group at R2 position results in nontoxic
compound. In AA C, the deletion of a “methoxy” group
from R1 and substitution of a “hydroxyl” group at R3
renders the compound nontoxic. In AA III, the shifting
of “methoxy” group from R1 position to R3 also makes
the compound nontoxic.
Addition of one hydroxyl group eliminates the toxic
nature of AA I. Toxicity is absent when a “hydroxyl”
group is added to either the R2 position (e.g., 7-OH AA
I), R3 position (e.g., AA-D) or R5 position (e.g., AA VIa).
During the process of nitroreduction, AA I loses a
major portion of its toxicity as evidenced from the non-
toxic nature of aristolactam compounds in LLC-PK1 cells.
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Reduction/methylation of dioxalane ring structure also
showed marked loss of toxicity.
Consistent with previous studies [46] we have found
that AA I is the most toxic compound in this renal cell
line. Aristolic acid and AA D, reported as less toxic com-
pound against P388 cell lines and Salmonella strains, are
also found to be non-toxic to LLC-PK1 cells. Aristolac-
tam I and aristolactam-N-beta-D-glucoside, which have
previously been shown to be toxic in cultured P388 and
human epidermoid carcinoma (KB) cells [46] were not
toxic in LLC-PK1 cells. This could be due to the variation
in cell lines and aristolactams might not be nephrotoxic.
Our observation of AA I as the most toxic compound
is in agreement with recent in vivo studies by Sato et al
[47]. They have also observed strongest nephrotoxic ef-
fect exerted by AA I and mild nephrotoxic effects by AA
II in mice. AA IVa and aristolactam I caused no renal
abnormality indicated by blood chemistry or histologic
change.
Mutagenic and carcinogenic effects of AA are asso-
ciated with the formation of AA-DNA adducts and the
extent of adduct formation largely depends on the struc-
ture of the compound. Several reports have identified AA
I and II as the major components of AA and they are
known to be genotoxic mutagens forming DNA adducts
after metabolic transformation [48, 49]. This is in line
with our observation of AA I and II as toxic compounds.
Nortier and Vanherwegham [50] have analysed tissue
samples from CHN patients and found the presence of
AA-related DNA adducts in 38/39 cases with high preva-
lence of urothelial carcinoma (46%). They found these
adducts to be most persistent as it was detected in kidney
tissue 89 months after the discontinuation of pill presum-
ably containing Aristolochia spp. The lifelong persistence
of AA-DNA adducts in AA toxic conditions makes their
detection in tissues a valid biologic marker ever years
after the cessation of AA exposure [11].
Nitro group is one of the functional group that has re-
ceived considerable attention from toxicity point of view.
Several studies have confirmed that the nitro group is im-
portant for the mutagenic activity of AA in Salmonella
and this mutagenecity was due to enzymic reduction of
the NO2 group to yield the hydroxylamino or even amino
analogues [51, 52]. Nitroreduction has been reported to
be the crucial step in the pathway of metabolic activa-
tion of AA to their ultimate mutagenic species and this
indicates the importance of nitro group in AA I moiety for
its toxic and carcinogenic properties. In the case of similar
nitro compounds like nitrobenzene [53] and nitrotoluene
[54] derivatives, the number and position of nitro group
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Table 2. Structural details of nitrophenantherene carboxylic compounds
O
O R4
O
OH
R5
R2
R1R3
Name R1 R2 R3 R4 R5 Chemical Name
AA I OCH3 H H NO2 H 8-methoxy-6-nitro-phenanthro- (3,4-d)-1,3-dioxolo-5-carboxylic acid
AA II H H H NO2 H 6-nitro-phenanthro- (3,4-d)-1,3-dioxolo-5-carboxylic acid
AA III H H OCH3 NO2 H 10-methoxy-6-nitro-phenanthro- (3,4-d)-1,3-dioxolo-5-carboxylic acid
AA Ia OH H H NO2 H 8-hydroxy-6-nitro-phenanthro- (3,4-d)-1,3-dioxolo-5-carboxylic acid
7-OH AA I OCH3 OH H NO2 H 8-methoxy-9-hydroxy-6-nitro-phenanthro- (3,4-d)-1,3-dioxolo-5-carboxylic acid
AA VIa OCH3 H H NO2 OH 8-methoxy-4 hydroxy-6-nitro-phenanthro- (3,4-d)-1,3-dioxolo-5-carboxylic acid
AA VIIIa OH OCH3 H NO2 H 8-hydroxy-9-methoxy-6-nitro-phenanthro- (3,4-d)-1,3-dioxolo-5-carboxylic acid
AA C H H OH NO2 H 10-hydroxy-6-nitro-phenanthro- (3,4-d)-1,3-dioxolo-5-carboxylic acid
AA D OCH3 H OH NO2 H 8-methoxy-10-hydroxy-6-nitro-phenanthro- (3,4-d)-1,3-dioxolo-5-carboxylic acid
Aristolic acid OCH3 H H H H 8-methoxy-phenanthro- (3,4-d)-1,3-dioxolo-5-carboxylic acid
Aristofolin B OCH3 OH H H H 8-methoxy-9-hydroxy–phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid
AA is aristolochic acid.
affects the toxicity. Even in the case of benzamines the
position of nitro group affected their mutagenic prop-
erties [55]. In all these compounds, the reduction of aro-
matic nitro group gives rise to toxic species and this shows
the functional importance of “nitro group” in toxicity.
Although several reports have suggested the functional
importance of the nitro group in AA mediated muta-
genicity/toxicity, the results from the present study sug-
gest that NO2 is not the only structural requirement for
AA-mediated cytotoxicity. The presence or absence of
methoxy and hydroxyl groups also plays a major role in
cytotoxicity. Although the results from Schmeiser et al
[51] have shown that the methoxy group is not required
for mutagenicity, our results suggest it is one of the essen-
tial structural requirements for nephrotoxicity. Pezzuto et
al [46] have also suggested that ring substituents of this
class of compounds could modulate biologic responses.
Sierra-Alvarez and Lettinga [56] have noticed that in-
crease in the number of methoxy, alkyl, or Cl groups can
increase the toxicity of aromatic compounds. Although,
this observation is in line with our finding of functional
importance of methoxy group, the true mechanism of in-
creased toxicity by the presence of methoxy group, and
reduced toxicity by the introduction of hydroxyl group
are still unclear and remains to be explored. But we sug-
gest that, the presence of hydroxyl group can make the
compound more water soluble and this can lead to in-
creased detoxification resulting in reduced toxicity.
The metabolism of AA has been studied in differ-
ent species, including humans, and has shown that the
products of nitroreduction (aristolactams) are the major
metabolites found in urine and feces [57]. Aristolactams
are not mutagenic themselves and require metabolic ac-
tivation by exogenous metabolic system whereas AA I
and AA II are direct mutagens in Salmonella strains [17].
The cellular injury mechanism of aristolactams was also
different from AA I [58].
On examination of the relevance of the present find-
ings about AA toxicity on proximal tubular cells to the
understanding of CHN, the proximal tubular cell damage
observed in the present toxicity studies might result in in-
flammation and fibrosis in CHN conditions. This in vitro
data can lead to the hypothesis that structure of AA com-
pounds plays a primary role in AA toxicity and result in
progressive kidney destruction in AA toxic/carcinogenic
conditions. The early development of tubular proteinuria
and glucosuria observed in CHN patients after AA in-
toxication, strongly suggest that proximal tubular cells
play a key role in pathogenesis of CHN patients [11].
According to recent review by Cosyns [11], only a small
fraction, about 3% to 5% of the patients who followed
slimming regimen at Belgian clinic, developed CHN. He
suggested that this low toxicity/carcinogenicity rate might
be due to the variation in the content of AA in the batches
of herbal pills. The present findings from our toxicity
studies suggest that the difference in the composition
of individual AA compounds (toxic versus nontoxic) in
those herbal preparations could have potentiated toxic-
ity/carcinogenicity in those cases. In several CHN patients
reported worldwide, the names of the consumed herbs
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are not reported [14, 59, 60] or available in Chinese and
Japanese characters only [21, 61, 62], although AA has
been identified in most of the herbal preparations used
by these patients. In such cases, based on our present find-
ings, we recommend, that both identification of herb as
well as the content of all these individual AA compounds
could be more helpful to understand the cause and extent
of toxicity. The toxic nature of the compounds AA VIIIa
and AA Ia reported from this data, in addition to known
toxic compounds AA I and II, emphasize the necessity for
identification of these compounds in CHN/AAN patients.
Role of caspases in AA-mediated nephrotoxicity
Caspases have emerged as powerful markers of cells
undergoing apoptosis. Caspase 3/7 are active cell death
proteases involved in the execution phase of apoptosis,
where cells undergo morphologic changes such as DNA
fragmentation, chromatin condensation, and apoptotic
body formation [63, 64]. Both caspase 3/7 are functionally
similar and have similar substrate specificities [65] and
cleavage of PARP during apoptosis may be due to a com-
bination of action of both these caspases [66]. To investi-
gate whether these executioner caspases were involved in
apoptotic mechanism caused by AA, caspase 3/7 activity
assay was performed. Our data suggest that AA com-
pounds activate these caspases, which could play a role
in AA-induced cell injury. Recently, Li et al [58] have
suggested the secretion of transforming growth factor-b
(TGF-b) 1 in AA I stimulated apoptosis in human kid-
ney (HK)-2 cells. As demonstrated in variety of cell lines
(hepatoma [67], human gastric cancer cells [68], and lym-
phoma cells [69]), it is known that, caspase 3 activation
is required for TGF-b–induced apoptosis. Thus, caspase
activation observed in our present study could mediate
apoptosis through TGF-b1 secretion. This finding may
be the starting point to investigate the molecular basis
for the requisite role of caspases in AA-induced nephro-
toxicity. Caspases could also serve as attractive potential
targets to modulate AA-induced injury in renal tubular
cells.
CONCLUSION
This study gives insights into the nephrotoxic potential
of AA I and its structural analogues. These observations
clearly indicate the importance of functional groups in
the order of nitro group (−NO2) > methoxy (−OCH3)
in terms of their potency to exert toxic properties. The ad-
dition of hydroxyl groups also renders the compound less
toxic/nontoxic. The AA I, the predominant constituent of
Aristolochia spp., is the most active compound in terms
of its cytotoxicity, and its structural analogues either have
less effect or no effect. The alterations in renal cellular
function could be greatly modified by the proportion of
AA I and its structural analogues. Tubular cell apopto-
sis mediated by caspase 3/7 activation might be one of
the mechanisms involved in this insult. Differences in
uptake, distribution, and metabolism of the AA deriva-
tives, however, may influence the in vivo toxicity of these
compounds.
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